Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioStem Technologies, Inc.BSEM · Entity 7054 | Chief Financial Officer | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioStem Technologies, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,062 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 1,694 · Balance 58,062 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,775 |
Reported balance
After 2026-09-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-15 · Exercise / conversion · Disposed 1,694 · Balance 6,775 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,591 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 21,591 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5: These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 96,909 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 96,909 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2035-08-19 | Direct | 38,814 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 38,814 F1: These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-02-11 | Direct | 117,401 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 117,401 F2: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F2: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
F5: These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
F6: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 1,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394397 · ownership.xml · derivative · entry 4 POE BRANDON · CIK 0002147189 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,775 Underlying: Common Stock · 1,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). F4 · derivative.expiration_date: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 1,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394397 · ownership.xml · nonDerivative · entry 1 POE BRANDON · CIK 0002147189 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2026 Filed Aug 20, 2026 23:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 10,634 | $0.00 | $0.00 |
DisclosureSEC source: 0002147189-26-000006 · ownership.xml · derivative · entry 5 POE BRANDON · CIK 0002147189 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,591 Underlying: Common Stock · 10,634 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Due to an administrative error, the vesting of the restricted stock units was not timely reported on a Form 4 within two business days of the applicable transaction date. F5 · derivative.expiration_date: These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Due to an administrative error, the vesting of the restricted stock units was not timely reported on a Form 4 within two business days of the applicable transaction date. Read SEC document |
| August 11, 2026 Filed Aug 20, 2026 23:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 10,634 | $0.00 | $0.00 |
DisclosureSEC source: 0002147189-26-000006 · ownership.xml · nonDerivative · entry 1 POE BRANDON · CIK 0002147189 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.